Telik (TELK) says it's completed its End of Phase 2 meeting with the FDA for its MDS treatment...

|By:, SA News Editor

Telik (TELK) says it's completed its End of Phase 2 meeting with the FDA for its MDS treatment Telintra, with a preliminary agreement reached regarding the design of a Phase 3 trials. In order to focus its resources on the registration program, Telik has decided to stop further enrollment in its ongoing Phase 2 exploratory trials.